Clonidine Augmentation Therapy in Schizophrenia - CATS (Clonidine Augmentation Therapy in Schizophrenia)

niversity Medical Center Utrecht0 个研究点目标入组 75 人开始时间: 2014年9月10日最近更新: 2015年1月12日

适应症

试验速览

暂无简介。

•1. A DSM-IV-R diagnosis of: 295.x (schizophrenia, schizophreniform disorder, or
•schizoaffective disorder)
•2. No or only partial response to clozapine as defined by a total PANSS score of at least 80.
•3. Age 18-45 years.
•4. Patients are treated with antipsychotic medication
•5. Written informed consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 75
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Presence of any of the contra-indications of clonidine as reported in the Summary of Product Characteristics (SPC).
•2. Supine systolic blood pressure (SSBP) < 85 mm HG
•3. Pre-existent orthostatic hypotension with a drop of systolic blood pressure of > 20 mmHg or a drop of diastolic blood pressure of >10 mmHg.
•4. Supine heart rate (SHR) < 50 beats/min
•5. Severe brady-arhytmias such as sick-sinussyndroom, second or third degree AV-block.
•6. Pregnancy or breast-feeding. A urine pregnancy test will be performed at screening.

发起方